Biotherapy of mice’s serum 13cH modifies parasitological and immunological parameters of Trypanosoma cruzi infection.

Background: T. cruzi biotherapies’ alter the infection course by this protozoan [1,2], fact that encourages evaluation of other highly diluted medicines which modulates host’s immune system. Aim: Evaluate effect biotherapy produced from mices’s serum in experimental cruzi. Methodology: A blind, randomized and controlled study was performed. Animals: 60 male Swiss mice, four weeks old were inoculated intraperitoneally with 1400 trypomastigotes-Y strain divided: MNI: mice non-infected cruzi; IC: treated hydroalcoholic solution 7%; BSI13cH: mice’s infected 13cH. Biotherapies: 13cH dynamization [3]. Treatment: 48 hours before after infection. Subsequently animals 56/56 until 9th day (d.i). The medicine water (1/100mL) offered ad libitum, for 16 hours. Parasitological parameters: evaluated pre-patent patent period, parasitemia peak, total mortality [4]. Cytokine dosage: IL-4, IL-17, TNF-α IFN-γ measured on 0, 8th 12th d.i., enzyme immunoassay. Ethics: approved Ethics Committee Experiments Animals/UEM. Statistic: data compared Mann Whitney or Student t test, significance 5%. Results: BSI13cH showed tendency to increase (p=0.06) peak (p=0.05), lower period (p=0.03) higher IC. In dosage cytokines group 0 d.i. a decrease IL-17 (p = 0.02) increased IL-4 0.01) MNI (baseline value), probably caused modulation medication administration concentration didn’t vary throughout BSI13cH, different IC tended cytokine significantly subsequent return baseline values. change value along 0.00) than IC, di. followed same evolution as an (Figure 1). seems initially promote Th2 response (IL-4), hindering development effective Th1 (INF-γ), causing animals' death. Conclusions: demonstrated parasitemia, animals’ premature death modulated differently